Mavenclad (cladribine) prevents relapses and disease progression in more than half of patients with relapsing forms of multiple sclerosis (MS) for at least five years after the last dose, according to a real-life study from Italy.
These findings, based on real-world data from Italian MS patients previously treated with Mavenclad in clinical trials, support the therapy’s long-term effectiveness.
While some patients switched to another treatment after a median of three years, this was not necessarily associated with relapse or disability progression, the researchers noted.
The study, “Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS),” was published in the journal Therapeutic Advances in Neurological Disorders.
Mavenclad, developed and marketed by EMD Serono (known as Merck KGaA outside North America), is an oral, short-course therapy approved for relapsing forms of MS in more than 50 countries, including those in the European Union, the U.S., Australia, and Canada.
Given in two treatment courses of two weeks each, separated by approximately one year, Mavenclad works by lowering the number of immune cells in the bloodstream, which are the cause of neurodegeneration in MS.
While results from clinical trials showed that Mavenclad led to sustained effectiveness up to four years after the last dose, longer-term data has to rely on patient registries and real-world studies.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?